Ticker Details
Rocket Pharmaceuticals, Inc. Rocket Pharmaceuticals Inc, formerly Inotek Pharmaceuticals Corp, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye.
IPO Date:	February 18, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$409.08M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.59 | 3.04%
Avg Daily Range (30 D):	$0.10 | 2.91%
Avg Daily Range (90 D):	$0.10 | 2.98%

Institutional Daily Volume
Avg Daily Volume:	.8M
Avg Daily Volume (30 D):	2.07M
Avg Daily Volume (90 D):	2.01M

Trade Size
Avg Trade Size (Sh.):	98
Avg Trade Size (Sh.) (30 D):	173
Avg Trade Size (Sh.) (90 D):	174

Institutional Trades
Total Institutional Trades:	2,717
Avg Institutional Trade:	$2.03M
Avg Institutional Trade (30 D):	$1.92M
Avg Institutional Trade (90 D):	$2M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.31M
Avg Closing Trade (30 D):	$.71M
Avg Closing Trade (90 D):	$.83M
Avg Closing Volume:	133.08K

News

Oct 23, 2025 @ 10:03 PM ROCKET ALERT: Bragar Eagel & Squire, P.C. is Inves... Source: Bragar Eagel & Squire, P.C.

Aug 11, 2025 @ 4:00 PM DEADLINE ALERT for RCKT, DDD, TEM, RDDT: Law Offic... Source: Law Offices Of Howard G. Smith

Aug 10, 2025 @ 3:38 PM RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR CO... Source: Rosen Law Firm

Aug 8, 2025 @ 4:38 PM Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT)... Source: Business Wire

Aug 7, 2025 @ 11:45 PM MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & ... Source: Robbins Geller Rudman & Dowd Llp

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS		$-.45	$-.62
Diluted EPS		$-.45	$-.62
Revenue		$M	$M
Gross Profit
Net Income / Loss		$-50.33M	$-68.92M
Operating Income / Loss		$-52.25M	$-71.15M
Cost of Revenue
Net Cash Flow		$43.13M	$-130.81M
PE Ratio

Splits
Jan 05, 2018	1:4